T
Tabea Moll
Researcher at Harvard University
Publications - 12
Citations - 1472
Tabea Moll is an academic researcher from Harvard University. The author has contributed to research in topics: Melanoma & Immunotherapy. The author has an hindex of 6, co-authored 11 publications receiving 727 citations. Previous affiliations of Tabea Moll include Rockefeller University & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon,Parin Shah,Michael S. Cuoco,Christopher Rodman,Mei-Ju Su,Johannes C. Melms,Rachel Leeson,Abhay Kanodia,Shaolin Mei,Jia-Ren Lin,Shu Wang,Bokang Rabasha,David Liu,Gao Zhang,Claire Margolais,Orr Ashenberg,Patrick A. Ott,Elizabeth I. Buchbinder,Rizwan Haq,F. Stephen Hodi,Genevieve M. Boland,Ryan J. Sullivan,Dennie T. Frederick,Benchun Miao,Tabea Moll,Keith T. Flaherty,Meenhard Herlyn,Russell W. Jenkins,Rohit Thummalapalli,Monika S. Kowalczyk,Israel Cañadas,Bastian Schilling,Bastian Schilling,Adam N.R. Cartwright,Adrienne M. Luoma,Shruti Malu,Patrick Hwu,Chantale Bernatchez,Marie Andrée Forget,David A. Barbie,Alex K. Shalek,Itay Tirosh,Peter K. Sorger,Kai W. Wucherpfennig,Eliezer M. Van Allen,Dirk Schadendorf,Bruce E. Johnson,Asaf Rotem,Asaf Rotem,Orit Rozenblatt-Rosen,Levi A. Garraway,Charles H. Yoon,Charles H. Yoon,Benjamin Izar,Aviv Regev +54 more
TL;DR: A resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion is identified, and this study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.
Journal ArticleDOI
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander,Gao Zhang,Joo Sang Lee,Joo Sang Lee,Dennie T. Frederick,Benchun Miao,Tabea Moll,Tian Tian,Zhi Wei,Sanna Madan,Sanna Madan,Ryan J. Sullivan,Genevieve M. Boland,Keith T. Flaherty,Meenhard Herlyn,Eytan Ruppin,Eytan Ruppin +16 more
TL;DR: IMPRES is a predictor of ICB response in melanoma which encompasses 15 pairwise transcriptomics relations between immune checkpoint genes and achieves an overall accuracy of AUC = 0.83, outperforming existing predictors and capturing almost all true responders while misclassifying less than half of the nonresponders.
Journal ArticleDOI
Spatially organized multicellular immune hubs in human colorectal cancer
Karin Pelka,Matan Hofree,Jonathan H. Chen,Siranush Sarkizova,Joshua D. Pirl,Vjola Jorgji,Alborz Bejnood,Danielle Dionne,William H. Ge,Katherine Xu,Sherry X. Chao,Daniel R. Zollinger,David J. Lieb,Jason Reeves,Christopher A. Fuhrman,Margaret L. Hoang,Toni Delorey,Lan T. Nguyen,Julia Waldman,Max Klapholz,Isaac Wakiro,Ofir Cohen,Julian Albers,Christopher Smillie,Michael S. Cuoco,Jingyi Wu,Mei-Ju Su,Jason Yeung,Brinda Vijaykumar,Angela M. Magnuson,Natasha Asinovski,Tabea Moll,Max N. Goder-Reiser,Anise S. Applebaum,Lauren K. Brais,Laura DelloStritto,Sarah L. Denning,Susannah T. Phillips,Emma K. Hill,Julia K. Meehan,Dennie T. Frederick,Tatyana Sharova,Abhay Kanodia,Ellen Todres,Judit Jané-Valbuena,Moshe Biton,Benjamin Izar,Conner Lambden,Thomas E. Clancy,Ronald Bleday,Nelya Melnitchouk,Jennifer Irani,Hiroko Kunitake,David H. Berger,Amitabh Srivastava,Jason L. Hornick,Shuji Ogino,Asaf Rotem,Sébastien Vigneau,Bruce E. Johnson,Ryan B. Corcoran,Arlene H. Sharpe,Vijay K. Kuchroo,Kimmie Ng,Marios Giannakis,Linda T. Nieman,Genevieve M. Boland,Andrew J. Aguirre,Ana C. Anderson,Orit Rozenblatt-Rosen,Aviv Regev,Aviv Regev,Nir Hacohen,Nir Hacohen +73 more
TL;DR: In this paper, the authors found a myeloid cell-attracting hub at the tumor-luminal interface associated with tissue damage and an MMRd-enriched immune hub within the tumor.
Journal ArticleDOI
Evolution of delayed resistance to immunotherapy in a melanoma responder
David Liu,David Liu,Jia-Ren Lin,Emily J. Robitschek,Emily J. Robitschek,Gyulnara G. Kasumova,Alexander Heyde,Alvin Shi,Alvin Shi,Adam A. Kraya,Gao Zhang,Gao Zhang,Tabea Moll,Dennie T. Frederick,Yu-An Chen,Shu Wang,Denis Schapiro,Denis Schapiro,Li Lun Ho,Li Lun Ho,Kevin Bi,Kevin Bi,Avinash Das Sahu,Shaolin Mei,Benchun Miao,Tatyana Sharova,Christopher Alvarez-Breckenridge,Jackson Stocking,Tommy Kim,Riley Fadden,Donald P. Lawrence,Mai P. Hoang,Daniel P. Cahill,Mohsen Malehmir,Mohsen Malehmir,Martin A. Nowak,Priscilla K. Brastianos,Christine G. Lian,Eytan Ruppin,Benjamin Izar,Meenhard Herlyn,Eliezer M. Van Allen,Eliezer M. Van Allen,Katherine L. Nathanson,Keith T. Flaherty,Ryan J. Sullivan,Manolis Kellis,Manolis Kellis,Peter K. Sorger,Genevieve M. Boland,Genevieve M. Boland +50 more
TL;DR: In this article, a high-resolution map of the evolutionary dynamics of resistance to ICB, characterizes a de-differentiated neural-crest tumor population in melanoma immunotherapy resistance and describes site-specific differences in tumor-immune interactions via longitudinal analysis of a patient with melanoma with an unusual clinical course.
Journal ArticleDOI
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Charles Marusak,Varsha Thakur,Yuan Li,Juliano T. Freitas,Patrick M. Zmina,Vijay S. Thakur,Mayland Chang,Ming Gao,Jiufeng Tan,Min Xiao,Yiling Lu,Gordon B. Mills,Keith T. Flaherty,Dennie T. Frederick,Benchun Miao,Ryan J. Sullivan,Tabea Moll,Genevieve M. Boland,Meenhard Herlyn,Gao Zhang,Barbara Bedogni +20 more
TL;DR: Investigation of the role of ECM remodeling by the collagenase, MT1-MMP, in conferring resistance of v-Raf murine sarcoma viral oncogene homolog B1-mutant melanoma to BRAF inhibitor (BRAFi) therapy found it pivotal to an ECM-based signaling pathway that confers resistance to BRAFi therapy.